FRAMINGHAM, Mass., April 17, 2018 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc. (CLS Americas) a subsidiary of CLS AB in Lund, Sweden, today announced the commencement of a clinical study with Toronto General Hospital in Canada investigating MRI-guided, focal laser ablation (FLA) treatments for prostate cancer.  The study has been approved by Health Canada and its results will be published on the National Institute of Health Web site: www.clinicaltrials.gov.

Starting in April 2018, twenty-five patients will participate in a 24-month study at the hospital to evaluate the safety and efficacy of CLS’s TRANBERG®|Thermal Therapy System and single-use accessories. The study includes men with early stage prostate cancer that have not already undergone radiation or hormone treatment.

“We are very pleased Toronto General Hospital has chosen our minimally invasive TRANBERG Thermal Therapy System for this important clinical study,” stated Lars-Erik Eriksson, CEO of Clinical Laserthermia Systems AB. “The study will produce important data surrounding the performance and efficacy of the TRANBERG Thermal Therapy System for MRI guided focal laser ablation treatments.”

Unique, Non-Cooled, Diffusing Fiber Technology
CLS utilizes unique, non-cooled, diffusing laser fiber technology to optimize heat distribution in tissue while eliminating the need for external cooling. The system also includes features designed to improve workflow and reduce procedure times.

About Clinical Laserthermia Systems
Clinical Laserthermia Systems AB (publ), develops and sells the TRANBERG®|Thermal Therapy System and specially-designed sterile disposable products for safe, gentle and effective treatment of cancerous tumors. The products are marketed for image-guided laser ablation and for treatment with immuno-stimulating interstitial laser thermotherapy, imILT®. The company, which is headquartered in Lund Sweden and has a subsidiary in Boston, MA, is listed Nasdaq First North under the ticker CLS B. Certified Adviser is Västra Hamnen Corporate Finance. Further information is available on www.clinicallaser.se.

The TRANBERG®|Thermal Therapy System has not yet received market clearance for immune stimulating interstitial laser thermotherapy (imILT®) by the Food and Drug Administration (FDA) in the United States of America (USA).

Media Contact
                  TopSpin Communications
                  Joe Waldygo
                  P: 480-363-8774
                  E: joe@topspinpr.com
                  
                  Company Contact
                  CLS Americas, Inc.
                  Alan Weinberg, General Manager 
                  P: 508-620-4521
                  E: alan@clinicallaser.se